Friday 16 October 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.06
0.06
+6.00%
Follow ALXO
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | — | 154.45 | — | — | — | — | — |
P/S ratio |
— | 25.44 | 25.44 | 653.57 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | (32.25) | 77.60 | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
— | (15.41) | (15.41) | (117.03) | — | — | — | — | — |
P/B ratio |
— | 0.00 | 0.00 | 3.71 | — | — | — | — | — |
Price to Tangible BV |
— | 0.00 | 0.00 | 3.71 | — | — | — | — | — |
EV/Sales |
— | 0.67 | 0.67 | 477.83 | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
— | (0.12) | (0.12) | (30.43) | — | — | — | — | — |
EV/FCF |
— | (0.12) | (0.12) | (30.40) | — | — | — | — | — |
Quick Ratio |
— | 4.91 | 1.92 | 69.99 | 23.78 | 9.40 | 5.08 | 6.91 | 1.82 |
Current Ratio |
— | 5.45 | 1.97 | 70.28 | 24.00 | 9.57 | 5.24 | 7.26 | 2.07 |
Net Debt/EBITDA |
— | 0.62 | 0.19 | 10.09 | 4.32 | 2.00 | 0.99 | 0.81 | 0.34 |
Debt/Assets |
0.00% | 0.00% | 50.78% | 0.00% | 0.68% | 3.40% | 3.97% | 6.70% | 16.51% |
Debt/Equity |
— | 0.00 | (0.08) | 0.00 | 0.01 | 0.04 | 0.05 | 0.09 | 0.38 |
Asset Turnover |
— | 0.00 | 0.90 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.76 | 0.61 | 0.75 | 0.82 | 0.72 | 0.81 | 0.90 | 0.83 |
Capex/Depreciation |
— | (1.52) | (0.80) | (0.05) | (96.53) | 2.58 | 0.24 | 0.13 | 0.83 |
Interest Coverage |
— | — | (913.48) | (53.84) | (6,427.31) | (535.45) | (108.80) | (82.40) | (64.93) |
| — | 28.43% | 38.02% | (28.36%) | (21.05%) | (39.42%) | (70.97%) | (88.91%) | (145.70%) | |
| — | 0.00% | (435.95%) | (22.81%) | (20.45%) | (35.97%) | (58.58%) | (69.10%) | (98.34%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (2,661.67%) | (1,036.13%) | (640.53%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (187.30%) | (409.34%) | (11.85%) | (23.67%) | (50.09%) | (102.92%) | (113.55%) | (371.50%) |
Average Days of Receivables |
— | 164.58 | 40.79 | 0.00 | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 545.23% | 339.99% | 2,450.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 125.83% | 69.08% | 1,252.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 13.01% | 6.19% | 459.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.91) | (0.91) | 0.27 | — | — | — | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
— | (28.29%) | (28.29%) | (8.13%) | — | — | — | — | — |
Free Cash Flow Yield |
— | (22.26%) | (22.26%) | (2.40%) | — | — | — | — | — |
Revenue per Share |
— | 0.75 | 1.56 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (4.79) | (4.63) | (2.07) | (1.69) | (2.19) | (3.03) | (2.34) | (1.57) |
Capex per Share |
— | (0.24) | (0.11) | 0.00 | (0.12) | (0.04) | (0.03) | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (5.03) | (4.75) | (2.07) | (1.81) | (2.23) | (3.06) | (2.35) | (1.57) |
Cash per Share |
— | 3.00 | 2.93 | 23.49 | 9.02 | 6.54 | 4.25 | 2.45 | 0.83 |
Shareholders Equity per Share |
— | 0.00 | (22.96) | 23.25 | 9.01 | 6.47 | 4.41 | 2.18 | 0.48 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (22.96) | 23.25 | 9.01 | 6.47 | 4.41 | 2.18 | 0.48 |
Free Cash Flow |
— | (13.84) | (14.60) | (38.32) | (73.02) | (90.65) | (131.64) | (122.36) | (84.35) |
Working Capital |
— | 8.34 | 4.83 | 429.79 | 351.72 | 242.64 | 152.66 | 115.85 | 26.17 |
Capital Expenditures |
— | (0.65) | (0.35) | (0.03) | (4.92) | (1.43) | (1.27) | (0.45) | (0.21) |
Net Current Asset Value |
— | 10.21 | (71.51) | 429.78 | 349.89 | 227.94 | 135.82 | 100.20 | 17.66 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
— | 0.32 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.45 | 0.51 | 11.98 | 0.06 | (0.14) | (1.50) | (1.21) | (0.21) |
Cash ROIC |
— | (167.55%) | 25.98% | (4.43%) | (10.01%) | (16.78%) | (34.45%) | (48.69%) | (104.76%) |
Accounts Receivable Turnover |
— | 2.82 | 6.53 | 0.00 | — | 0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.85 | 1.96 | 0.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 135.32 | 313.77 | 1.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.73 | 0.73 | — | — | 0.77 | — | — | — |
Average Payables |
— | 2.22 | 2.22 | 1.88 | 1.88 | 5.92 | 8.33 | 6.54 | 4.71 |
Average Assets |
— | 0.00 | 5.34 | 223.37 | 408.12 | 343.34 | 274.52 | 195.16 | 103.41 |
Average Common Equity |
— | (61.21) | (61.21) | 179.60 | 396.45 | 313.26 | 226.59 | 151.67 | 69.80 |
Columns are period end dates